AstraZeneca PLC (NASDAQ:AZN) is one of Goldman Sachs’ top healthcare stock picks. On July 4, the company secured regulatory approval for Imfinzi (durvalumab). The approval is for the use of the drug ...

AstraZeneca’s drug candidate baxdrostat lowered systolic blood pressure in a phase 3 clinical trial involving patients with uncontrolled or treatment-resistant hypertension. In the trial, patients who ...

Baxdrostat, which AstraZeneca acquired in a 2023 buyout of CinCor Pharma, could become a new treatment for people whose ...

The government must urgently abolish stamp duty on shares and abolish new cash ISAs to prevent the London Stock Exchange ...

Multinational pharmaceutical maker AstraZeneca said Tuesday it will pay $425 million to settle lawsuits from people who experienced kidney damage from the company's heartburn medications Nexium ...

AstraZeneca Plc AZN has agreed to pay $425 million to settle U.S. lawsuits related to heartburn and stomach acid treatments Nexium and Prilosec. The heartburn treatments have been under litigation ...

(RTTNews) - British drug major AstraZeneca Plc (AZN.L, AZN) announced Tuesday that it has entered into settlement agreements in the product liability litigations related to Nexium and Prilosec ...

British drugmaker AstraZeneca on Tuesday said it will pay $425 million to settle product liability litigations against prescription-only acid-reflux medicine Nexium and heartburn drug Prilosec in ...

(RTTNews) - British drug major AstraZeneca Plc (AZN.L, AZN) announced Tuesday that it has entered into settlement agreements in the product liability litigations related to Nexium and Prilosec ...

AstraZeneca has agreed to pay $425 million to settle product liability suits over two heartburn drugs, Prilosec and Nexium.